Food Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa, Japan.
Department of Nursing, Matsumoto Junior College, Matsumoto, Nagano, Japan.
Clin Interv Aging. 2020 May 27;15:743-754. doi: 10.2147/CIA.S253116. eCollection 2020.
Preventative measures have recently been taken to reduce the incidence of Alzheimer's disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood-brain barrier, attenuated cognitive decline in a mouse model of Alzheimer's disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia.
A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 μg MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety.
The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration ( = 0.022). No serious adverse events due to MKP intake were observed.
To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function.
最近采取了预防措施来降低全球阿尔茨海默病的发病率。我们之前的研究表明,MKP(一种具有潜在血脑屏障穿透能力的酪蛋白衍生血管紧张素转换酶抑制肽)可减轻阿尔茨海默病小鼠模型的认知能力下降。然而,MKP 对人类认知功能改善的影响尚不清楚。本探索性研究旨在调查 MKP 摄入是否可以改善无痴呆的成年人的认知功能。
共有 268 名无痴呆的社区居民参与了这项为期 24 周的随机对照试验。参与者被随机分配到 MKP(n = 134)或安慰剂(n = 134)组。MKP 组每天服用 4 片,每片含 50 μg MKP,而安慰剂组每天服用 4 片不含可检测到的 MKP 的糊精片,共 24 周。使用阿尔茨海默病评估量表(ADAS-cog)认知子量表的日本版本评分作为主要结局来比较 MKP 和安慰剂组之间的认知功能。还对研究产品的安全性进行了评估。
意向治疗分析显示,MKP 组与安慰剂组之间的 ADAS-cog 总分无显著差异。与安慰剂组相比,MKP 给药 24 周后,定向(分别通过 ADAS-cog 子量表测量)显著改善( = 0.022)。未观察到因摄入 MKP 引起的严重不良事件。
据我们所知,这是第一项报道 MKP 对人类认知影响的研究。这些初步结果表明,每天摄入 MKP 是安全的,并且可能改善无痴呆成年人的定向能力。需要进一步的临床研究来证实目前的发现和 MKP 对认知功能的益处。